Related news from
Tue, 14 May 2024 16:56:00 +0000	Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
Tue, 14 May 2024 14:02:00 +0000	Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
Tue, 14 May 2024 13:25:00 +0000	Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
Tue, 14 May 2024 12:57:00 +0000	Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
Mon, 13 May 2024 16:00:11 +0000	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Mon, 13 May 2024 15:25:00 +0000	Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
Mon, 13 May 2024 15:16:00 +0000	Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
Fri, 10 May 2024 15:33:00 +0000	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
Fri, 10 May 2024 15:14:00 +0000	Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
Fri, 10 May 2024 14:58:00 +0000	Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
Fri, 10 May 2024 14:46:00 +0000	Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
Fri, 10 May 2024 12:50:07 +0000	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why Ligand (LGND) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Thu, 09 May 2024 15:40:00 +0000	Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
Thu, 09 May 2024 14:58:00 +0000	CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
Thu, 09 May 2024 13:40:11 +0000	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
Thu, 09 May 2024 11:26:23 +0000	Ligand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023) Ligand Pharmaceuticals ( NASDAQ:LGND ) First Quarter 2024 Results Key Financial Results Revenue: US$31.0m (down 30...
Thu, 09 May 2024 09:59:00 +0000	Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
Wed, 08 May 2024 17:22:24 +0000	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript May 7, 2024 Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13. LGND isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. Our […]
Wed, 08 May 2024 16:20:00 +0000	Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Wed, 08 May 2024 16:19:00 +0000	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.